These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 9165568

  • 1. Neuroleptic malignant syndrome with risperidone.
    Gleason PP, Conigliaro RL.
    Pharmacotherapy; 1997; 17(3):617-21. PubMed ID: 9165568
    [Abstract] [Full Text] [Related]

  • 2. [Malignant neuroleptic syndrome associated to risperidone].
    Aguirre C, García Monco JC, Mendibil B.
    Med Clin (Barc); 1998 Feb 21; 110(6):239. PubMed ID: 9547739
    [No Abstract] [Full Text] [Related]

  • 3. [Neuroleptic malignant syndrome in users of risperidone].
    Gerritsen AA, de Jonghe-Rouleau AP, Stienstra-Liem LH.
    Ned Tijdschr Geneeskd; 2004 Sep 11; 148(37):1801-4. PubMed ID: 15495506
    [Abstract] [Full Text] [Related]

  • 4. Risperidone and neuroleptic malignant syndrome.
    Tarsy D.
    JAMA; 1996 Feb 14; 275(6):446. PubMed ID: 8627964
    [No Abstract] [Full Text] [Related]

  • 5. Risperidone: an analysis of the first three years in general use.
    Gutierrez-Esteinou R, Grebb JA.
    Int Clin Psychopharmacol; 1997 Sep 14; 12 Suppl 4():S3-10. PubMed ID: 9352340
    [Abstract] [Full Text] [Related]

  • 6. [Risperidone].
    Zolk O, Thürauf N.
    Dtsch Med Wochenschr; 2003 Jun 13; 128(24):1353-6. PubMed ID: 12802745
    [No Abstract] [Full Text] [Related]

  • 7. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S, Kornreich C, Choubani Z, Gourevitch R.
    Encephale; 2008 Dec 13; 34(6):618-24. PubMed ID: 19081460
    [Abstract] [Full Text] [Related]

  • 8. [Neuroleptic malignant syndrome in users of risperidone].
    Kroon JG.
    Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):157-8; author reply 158. PubMed ID: 15693594
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Neuroleptic malignant syndrome in users of risperidone].
    Vorel SK, Bos F, Vorel-Havelkova E, Brombacher PJ.
    Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):159-60; author reply 160. PubMed ID: 15693596
    [No Abstract] [Full Text] [Related]

  • 11. [Neuroleptic malignant syndrome in users of risperidone].
    Bonte-Mineur F, Geerlings CJ, Rietveld AP.
    Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):158-9; author reply 159. PubMed ID: 15693595
    [No Abstract] [Full Text] [Related]

  • 12. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
    Liu PY, Wu PC, Chen CY, Chen YC.
    Gen Hosp Psychiatry; 2011 Jan 15; 33(1):84.e5-7. PubMed ID: 21353143
    [Abstract] [Full Text] [Related]

  • 13. [Neuroleptic malignant syndrome in users of risperidone].
    van Waarde JA, Kuiper J, Verwey B.
    Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):156-7; author reply 157. PubMed ID: 15693593
    [No Abstract] [Full Text] [Related]

  • 14. Novel versus conventional antipsychotic drugs.
    Love RC.
    Pharmacotherapy; 1996 Jan 15; 16(1 Pt 2):6-10. PubMed ID: 8778684
    [Abstract] [Full Text] [Related]

  • 15. [A study of neuroleptic malignant syndrome in the presenium and senium].
    Suzuki I, Honma H, Watanabe N, Matsubara S, Koyama T.
    Seishin Shinkeigaku Zasshi; 1998 Jan 15; 100(6):387-97. PubMed ID: 9745353
    [Abstract] [Full Text] [Related]

  • 16. Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report.
    Mall GD, Hake L, Benjamin AB, Adityanjee A.
    J Clin Psychopharmacol; 2008 Oct 15; 28(5):572-3. PubMed ID: 18794658
    [No Abstract] [Full Text] [Related]

  • 17. Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome.
    Vurucu S, Congologlu A, Altun D, Unay B, Akin R.
    J Natl Med Assoc; 2009 Mar 15; 101(3):273-5. PubMed ID: 19331262
    [Abstract] [Full Text] [Related]

  • 18. A Case of neuroleptic malignant syndrome accompanied to an atypical antipsychotic agent: risperidone.
    Pasa S, Sayhan MB, Boyraz T, Urakci Z, Altintas A.
    Neurotoxicology; 2008 Jul 15; 29(4):750-1. PubMed ID: 18539333
    [No Abstract] [Full Text] [Related]

  • 19. Risperidone.
    Cohen LJ.
    Pharmacotherapy; 1994 Jul 15; 14(3):253-65. PubMed ID: 7524043
    [Abstract] [Full Text] [Related]

  • 20. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
    Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T.
    Synapse; 2002 Oct 15; 46(1):32-7. PubMed ID: 12211096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.